Qingdao Vland Biotech INC.

Equities

603739

CNE100003GX8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
11.46 CNY +9.98% Intraday chart for Qingdao Vland Biotech INC. +18.14% -24.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders. CI
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan MT
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million. CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd. CI
Archer Daniels Midland : to Create Human Probiotics Joint Venture With Qingdao Vland Biotech Group MT
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Qingdao Vland Biotech INC. announced that it has received CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd. CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the Nine Months Ended September 30, 2020 CI
Qingdao Vland Biotech INC. announced that it expects to receive CNY 499.999984 million in funding from Tibet Shancheng Investment Consulting Co., Ltd., Tibet Sizhuang Investment Consulting Co., Ltd. CI
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2020 CI
Qingdao Vland Biological Products Co., Ltd. announced that it has received CNY 430 million in funding from Qingdao Vland Biotech INC. CI
Chart Qingdao Vland Biotech INC.
More charts
Qingdao Vland Biotech Co., Ltd. is a China-based company which mainly develops, produces and sells enzyme preparations, micro-ecology and animal health products. The Company's main products are enzyme preparations, micro-ecology and animal health products, such as feed enzymes, industrial enzymes, food enzymes, plant micro-ecological preparations, veterinary chemicals and veterinary drugs. The Company's products are mainly used in the washing, textile, food, feed, paper, energy and pharmaceutical industries. The Company mainly distributes its products in China and overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
11.46
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603739 Stock
  4. News Qingdao Vland Biotech INC.
  5. Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan